Literature DB >> 29616131

Chemoprevention with phosphatidylcholine non-steroidal anti-inflammatory drugs in vivo and in vitro.

Lenard M Lichtenberger1, Tri Phan1, Dexing Fang1, Elizabeth J Dial1.   

Abstract

The chemopreventive activity of non-steroidal anti-inflammatory drugs (NSAIDs), particularly aspirin, has been well demonstrated in preclinical and clinical studies. However, the primary side effect from this class of drug is gastrointestinal (GI) bleeding, which has limited the widespread use of NSAIDs for the prevention of cancer. The development of GI-safer NSAIDs, which are associated with phosphatidylcholine (PC) may provide a solution to this therapeutic problem. In the present study, the efficacy of two NSAIDs, aspirin and indomethacin, were compared using murine colon cancer cell line MC-26. Each NSAID was assessed alone and in combination with PC, using in vitro and in vivo systems. The results reveal that the PC-associated NSAIDs had a significantly higher degree of protection against cancer cell growth compared with the unmodified NSAIDs. It was also observed that Aspirin-PC and Indomethacin-PC prevented the metastatic spread of cancer cells in a syngeneic mouse model. These results support the potential use of PC-NSAIDs for the chemoprevention of colorectal cancer.

Entities:  

Keywords:  aspirin; chemoprevention; colorectal cancer; indomethacin; non-steroidal anti-inflammatory drug

Year:  2018        PMID: 29616131      PMCID: PMC5876429          DOI: 10.3892/ol.2018.8098

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  33 in total

1.  Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer.

Authors:  Yan Huang; Lenard M Lichtenberger; Morgan Taylor; Justin N Bottsford-Miller; Monika Haemmerle; Michael J Wagner; Yasmin Lyons; Sunila Pradeep; Wei Hu; Rebecca A Previs; Jean M Hansen; Dexing Fang; Piotr L Dorniak; Justyna Filant; Elizabeth J Dial; Fangrong Shen; Hiroto Hatakeyama; Anil K Sood
Journal:  Mol Cancer Ther       Date:  2016-09-16       Impact factor: 6.261

Review 2.  Beyond COX-inhibition: 'side-effects' of ibuprofen on neoplastic development and progression.

Authors:  Paulo Matos; Peter Jordan
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

Review 3.  Mechanisms of nonsteroidal anti-inflammatory drugs in cancer prevention.

Authors:  Asad Umar; Vernon E Steele; David G Menter; Ernest T Hawk
Journal:  Semin Oncol       Date:  2015-09-10       Impact factor: 4.929

Review 4.  NSAIDs inhibit tumorigenesis, but how?

Authors:  Evrim Gurpinar; William E Grizzle; Gary A Piazza
Journal:  Clin Cancer Res       Date:  2013-12-05       Impact factor: 12.531

5.  Surface phospholipids in gastric injury and protection when a selective cyclooxygenase-2 inhibitor (Coxib) is used in combination with aspirin.

Authors:  L M Lichtenberger; J J Romero; E J Dial
Journal:  Br J Pharmacol       Date:  2007-02-26       Impact factor: 8.739

6.  Phosphatidylcholine-associated nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit DNA synthesis and the growth of colon cancer cells in vitro.

Authors:  Elizabeth J Dial; J Rand Doyen; Lenard M Lichtenberger
Journal:  Cancer Chemother Pharmacol       Date:  2005-07-20       Impact factor: 3.333

7.  The effect of indomethacin on food and water intake, motor activity and survival in tumour-bearing rats.

Authors:  R Sandström; J Gelin; K Lundholm
Journal:  Eur J Cancer       Date:  1990       Impact factor: 9.162

8.  Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer.

Authors:  Min Yao; Wei Zhou; Simren Sangha; Andrew Albert; Albert J Chang; Thomas C Liu; M Michael Wolfe
Journal:  Clin Cancer Res       Date:  2005-02-15       Impact factor: 12.531

Review 9.  Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review).

Authors:  Randall E Harris; Joanne Beebe-Donk; Hani Doss; Deborah Burr Doss
Journal:  Oncol Rep       Date:  2005-04       Impact factor: 3.906

10.  Antitumor activity of indomethacin in mice bearing advanced colon 26 carcinoma compared with those with early transplants.

Authors:  Y Tanaka; T Tanaka; H Ishitsuka
Journal:  Cancer Res       Date:  1989-11-01       Impact factor: 12.701

View more
  4 in total

1.  Diclofenac down-regulates COX-2 induced expression of CD44 and ICAM-1 in human HT29 colorectal cancer cells.

Authors:  Çağatay Yilmaz; Sadi Köksoy; Tuğçe Çeker; Mutay Aslan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-08-26       Impact factor: 3.195

Review 2.  Unboxing the molecular modalities of mutagens in cancer.

Authors:  Smita Kumari; Sudhanshu Sharma; Dia Advani; Akanksha Khosla; Pravir Kumar; Rashmi K Ambasta
Journal:  Environ Sci Pollut Res Int       Date:  2021-10-05       Impact factor: 5.190

3.  Growth inhibitory effects of PC-NSAIDs on human breast cancer subtypes in cell culture.

Authors:  Shelley Burge; Lenard M Lichtenberger
Journal:  Oncol Lett       Date:  2019-10-02       Impact factor: 2.967

4.  Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development.

Authors:  Jennifer S Davis; Preeti Kanikarla-Marie; Mihai Gagea; Patrick L Yu; Dexing Fang; Manu Sebastian; Peiying Yang; Ernest Hawk; Roderick Dashwood; Lenard M Lichtenberger; David Menter; Scott Kopetz
Journal:  BMC Cancer       Date:  2020-09-10       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.